Study of ABT-888 in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Refractory Myeloma

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

February 28, 2015

Study Completion Date

February 10, 2015

Conditions
Multiple Myeloma
Interventions
DRUG

ABT-888/Bortezomib

ABT-888 is given orally (PO) twice daily (every 12 hours) for 14 days in a 21 days cycle. First dose to be given within 1 hour of Bortezomib on day 1. Planned starting dose is 20 mg PO every 12 hours. Starting dose escalation is planned until an MTD is reached.

Trial Locations (1)

T2N 4N2

Tom Baker Cancer Centre, Calgary

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Tom Baker Cancer Centre

OTHER

collaborator

Abbott

INDUSTRY

lead

AHS Cancer Control Alberta

OTHER

NCT01495351 - Study of ABT-888 in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Refractory Myeloma | Biotech Hunter | Biotech Hunter